Granite Point Capital Management, L.P. Bluebird Bio, Inc. Transaction History

Granite Point Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$11.24 - $21.0 $1.46 Million - $2.73 Million	-130,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $1.98 Million - $2.43 Million	-110,000 Reduced 45.83%	130,000 $4.16 Million
Q1 2021 May 12, 2021	BUY	$16.59 - $33.89 $3.98 Million - $8.13 Million	240,000 New	240,000 $7.24 Million

170

104M

814K

1.23M

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $81M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.